DrugPatentWatch Database Preview
Minocycline hydrochloride - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic sources for minocycline hydrochloride and what is the scope of freedom to operate?
Minocycline hydrochloride
is the generic ingredient in seven branded drugs marketed by Sun Pharm Inds Inc, Cnty Line Pharms, Bausch, Triax Pharms, Aurobindo Pharma, Impax Labs, Torrent, Watson Labs, Watson Labs Teva, Zydus, Lederle, Rempex Pharms, Orapharma, Alkem Labs Ltd, Aurobindo Pharma Ltd, Barr Labs Inc, Impax Labs Inc, Lupin Ltd, Mylan, Mylan Labs Ltd, Mylan Pharms Inc, Sandoz, Sidmak Labs India, Sun Pharm Inds Ltd, Zydus Pharms, Epi Hlth, Medicis, Dr Reddys Labs Ltd, Par Pharm, and Sun Pharm Industries, and is included in thirty-five NDAs. There are twelve patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Minocycline hydrochloride has fifty-nine patent family members in twenty-six countries.
There are fifteen drug master file entries for minocycline hydrochloride. Forty-nine suppliers are listed for this compound. There are five tentative approvals for this compound.
Summary for minocycline hydrochloride
| International Patents: | 59 |
| US Patents: | 12 |
| Tradenames: | 7 |
| Applicants: | 30 |
| NDAs: | 35 |
| Drug Master File Entries: | 15 |
| Suppliers / Packagers: | 49 |
| Bulk Api Vendors: | 79 |
| Clinical Trials: | 202 |
| Patent Applications: | 2,930 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for minocycline hydrochloride |
| DailyMed Link: | minocycline hydrochloride at DailyMed |
Recent Clinical Trials for minocycline hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Riyadh Elm University | N/A |
| Dow University of Health Sciences | Phase 1/Phase 2 |
| Sun Yat-sen University | Phase 2 |
Recent Litigation for minocycline hydrochloride
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Apotex Inc. v. Wyeth LLC | 2015-07-29 |
| Medicis Pharmaceutical Corporation v. Alkem Laboratories Ltd. | 2012-12-05 |
| Medicis Pharmaceutical Corporation v. Zydus Pharmaceuticals USA Inc. | 2012-06-04 |
Generic filers with tentative approvals for MINOCYCLINE HYDROCHLORIDE
| Applicant | Application No. | Strength | Dosage Form |
| Start Trial | Start Trial | EQ 80MG BASE | Tablet, Extended Release; Oral |
| Start Trial | Start Trial | EQ 55MG BASE | TABLET, EXTENDED RELEASE; ORAL |
| Start Trial | Start Trial | EQ 115MG BASE | TABLET, EXTENDED RELEASE; ORAL |
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for minocycline hydrochloride
| Drug Class | Tetracycline-class Drug |
Medical Subject Heading (MeSH) Categories for minocycline hydrochloride
Synonyms for minocycline hydrochloride
| (2E,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride |
| (2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride |
| (4S-(4alpha,4aalpha,5aalpha,12aalpha))-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride |
| (4S,12aS,4aS,5aR)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide Hydrochloride |
| (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride |
| [4S-(4?,4a?,5a?,12a?)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide |
| [4S-(4|A,4a|A,5a|A,12a|A)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-2-naphthacenecarboxamide Hydrochloride |
| [4S-(4|A,4a|A,5a|A,12a|A)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride |
| [4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide |
| [4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride |
| 0020414E5U |
| 10118-90-8 (base) |
| 10118-90-8 (Parent) |
| 1071702-75-4 |
| 11006-27-2 |
| 1236362-29-0 |
| 13614-98-7 |
| 150231-24-6 |
| 2-Naphthacenecarboxamide, 4,7- bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11dioxo-, monohydrochloride, [4S-(4alpha,4aalpha,5aalpha,12aalpha)] |
| 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride |
| 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, (4S-(4alpha,4aalpha,5aalpha,12aalpha))- |
| 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride |
| 614M987 |
| 7-Dimethylamino-6-demethyl-6-deoxytetracycline, HCl |
| AB1009463 |
| AC-22362 |
| AC1NQY0N |
| AC1NSG07 |
| Acnez |
| AKOS015951312 |
| Arestin |
| Arestin (TN) |
| BC207859 |
| BCP06597 |
| C23H27N3O7.HCl |
| C23H28ClN3O7 |
| CAS-13614-98-7 |
| CCG-40107 |
| CHEBI:50697 |
| CHEMBL1200881 |
| CS-1256 |
| D00850 |
| DSSTox_CID_24545 |
| DSSTox_GSID_44545 |
| DSSTox_RID_80306 |
| DTXSID8044545 |
| Dynacin |
| Dynacin (TN) |
| EINECS 237-099-7 |
| FT-0082736 |
| FT-0601821 |
| FXFM-244 |
| GLMUAFMGXXHGLU-VQAITOIOSA-N |
| HMS1568P12 |
| HY-17412 |
| J10198 |
| KB-274624 |
| Klinomycin |
| KS-00000XT8 |
| Lederderm |
| LS-91518 |
| LS-93852 |
| M2288 |
| MFCD00083669 |
| MINO |
| Minocin |
| Minocin (TN) |
| Minocycline (hydrochloride) |
| Minocycline chloride |
| Minocycline HCl |
| Minocycline hydrochloride (internal use) |
| Minocycline hydrochloride (JP17/USP) |
| Minocycline hydrochloride [USAN:JAN] |
| Minocycline hydrochloride [USP:JAN] |
| Minocycline hydrochloride, 97% |
| Minocycline hydrochloride, Antibiotic for Culture Media Use Only |
| Minocycline hydrochloride, crystalline |
| Minocycline hydrochloride, European Pharmacopoeia (EP) Reference Standard |
| Minocycline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material |
| Minocycline hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Minocycline, HCl |
| Minocycline, Hydrochloride |
| Minocyclinhydrochlorid |
| Minomax |
| Minomycin |
| Minomycin chloride |
| minomycin hydrochloride |
| MLS002548863 |
| MolPort-003-666-235 |
| MolPort-042-652-589 |
| Mynocine |
| Mynocine hydrochloride |
| NC00460 |
| NCGC00096006-01 |
| NCGC00178854-03 |
| NCGC00255988-01 |
| NSC-757120 |
| NSC757120 |
| Periocline |
| Pharmakon1600-01500414 |
| Prestwick_626 |
| Q-201407 |
| S051 |
| s4226 |
| SC-19210 |
| SCHEMBL2537 |
| SMR001906766 |
| Solodyn |
| Solodyn (TN) |
| SPECTRUM1500414 |
| SR-01000075625 |
| SR-01000075625-1 |
| ST24034766 |
| Tox21_111250 |
| Tox21_111250_1 |
| Tox21_113183 |
| Tox21_301590 |
| Tri-mino |
| Tri-minocycline |
| UNII-0020414E5U |
| Vectrin |
| W-5076 |
| Ximino |
Paragraph IV (Patent) Challenges for MINOCYCLINE HYDROCHLORIDE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| SOLODYN | TABLET, EXTENDED RELEASE;ORAL | minocycline hydrochloride | 050808 | 2010-12-13 |
| SOLODYN | TABLET, EXTENDED RELEASE;ORAL | minocycline hydrochloride | 050808 | 2010-12-02 |
| SOLODYN | TABLET, EXTENDED RELEASE;ORAL | minocycline hydrochloride | 050808 | 2010-10-27 |
| SOLODYN | TABLET, EXTENDED RELEASE;ORAL | minocycline hydrochloride | 050808 | 2009-11-19 |
US Patents and Regulatory Information for minocycline hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-003 | Jul 11, 2012 | RX | No | No | Start Trial | Start Trial | Start Trial | ||||
| Medicis | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-006 | Aug 27, 2010 | AB | RX | Yes | No | Start Trial | Start Trial | Start Trial | |||
| Mylan Labs Ltd | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201467-002 | Jul 30, 2019 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Mylan Pharms Inc | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 090911-001 | Jul 20, 2010 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| Aurobindo Pharma Ltd | MINOCYCLINE HYDROCHLORIDE | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 202261-005 | Nov 19, 2012 | AB | RX | No | No | Start Trial | Start Trial | Start Trial | |||
| Sun Pharm Inds Inc | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-005 | Jul 11, 2012 | RX | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for minocycline hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Medicis | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-001 | May 8, 2006 | Start Trial | Start Trial |
| Sun Pharm Inds Inc | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-003 | Jul 11, 2012 | Start Trial | Start Trial |
| Medicis | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-007 | Aug 27, 2010 | Start Trial | Start Trial |
| Sun Pharm Inds Inc | XIMINO | minocycline hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 201922-001 | Jul 11, 2012 | Start Trial | Start Trial |
| Medicis | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-008 | Aug 27, 2010 | Start Trial | Start Trial |
| Medicis | SOLODYN | minocycline hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 050808-004 | Jul 23, 2009 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for minocycline hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2647972 | Start Trial |
| Colombia | 6650346 | Start Trial |
| Japan | 4749672 | Start Trial |
| Japan | 2013529201 | Start Trial |
| Australia | 2011252919 | Start Trial |
| Spain | 2715551 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.